Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2026
Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trialMonique C de Jong, Andrew J Hope, José S A Belderbos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2018
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural MesotheliomaJosine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, et al.
European Urology Open Science|January 13, 2022
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data AssessmentAafke Meerveld-Eggink, Niels Graafland, Sofie Wilgenhof, et al.
Physics and Imaging in Radiation Oncology|April 9, 2026
Magnetic resonance imaging thoracic organ-at-risk atlas for radiation oncologyHannah Bainbridge, Michael J Dubec, Andreas Wetscherek, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung CancerRosemarie de Haan, Michel M van den Heuvel, Judi van Diessen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 27, 2023
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trialSaskia A Cooke, Dirk de Ruysscher, Bart Reymen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trialCornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, et al.
Pageof 3